Detalhe da pesquisa
1.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(11): 1599-1611, 2016 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-27720136